Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-05-17
2008-12-16
Saeed, Kamal A (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S253000, C548S268600, C548S204000, C562S472000, C562S469000
Reexamination Certificate
active
07465804
ABSTRACT:
The present invention provides compounds useful, for example, for modulating insulin levels in a subject, having the general formula I:wherein Q is an optionally substituted phenyl; L is a bond or O; P is a benzene or an optionally substituted thiazole ring; and R1has the values provided herein. The present invention also provides compositions, uses, and methods for use of the compounds, for instance, for treatment of type II diabetes.
REFERENCES:
patent: 4760089 (1988-07-01), Chambers et al.
patent: 6037367 (2000-03-01), Christensen, IV et al.
patent: 6476052 (2002-11-01), Muller et al.
patent: 6506757 (2003-01-01), Tajima et al.
patent: 6710063 (2004-03-01), Chao et al.
patent: 6723740 (2004-04-01), Chao et al.
patent: 6875780 (2005-04-01), Auerbach et al.
patent: 6939875 (2005-09-01), Auerbach et al.
patent: 6964983 (2005-11-01), Auerbach et al.
patent: 7338960 (2008-03-01), Bell et al.
patent: 7345068 (2008-03-01), Endou et al.
patent: 2004/0058965 (2004-03-01), Momose et al.
patent: 2005/0119256 (2005-06-01), Endo et al.
patent: 2006/0003344 (2006-01-01), Houseknecht et al.
patent: 2006/0004012 (2006-01-01), Akerman et al.
patent: 2007/0142384 (2007-06-01), Akerman et al.
patent: 2007/0265332 (2007-11-01), Ge et al.
patent: 2111035 (1994-06-01), None
patent: 27 33 305 (1977-07-01), None
patent: 42 41 632 (1994-06-01), None
patent: 199 4 1 567 (2000-04-01), None
patent: 0 250 264 (1987-12-01), None
patent: 1 357 115 (2003-10-01), None
patent: 1 380 562 (2004-01-01), None
patent: 1 535 915 (2005-06-01), None
patent: 1 559 422 (2005-08-01), None
patent: 1 630 152 (2006-03-01), None
patent: 10316641 (1998-02-01), None
patent: WO 93/23040 (1993-11-01), None
patent: WO 93/23041 (1993-11-01), None
patent: WO 95/01326 (1995-01-01), None
patent: WO 95/01348 (1995-01-01), None
patent: WO 97/12867 (1997-04-01), None
patent: WO 00/68223 (2000-11-01), None
patent: WO 01/00603 (2001-01-01), None
patent: WO 01/36351 (2001-05-01), None
patent: WO 01/36365 (2001-05-01), None
patent: WO 02/053547 (2002-07-01), None
patent: WO 02/057783 (2002-07-01), None
patent: WO 02/062774 (2002-08-01), None
patent: WO 02/100403 (2002-12-01), None
patent: WO 02/100812 (2002-12-01), None
patent: WO 03/068959 (2003-08-01), None
patent: WO 03/074050 (2003-09-01), None
patent: WO 03/099793 (2003-12-01), None
patent: WO 2004/000315 (2003-12-01), None
patent: WO 2004/022551 (2004-03-01), None
patent: WO 2004/041266 (2004-05-01), None
patent: WO 2004/106276 (2004-12-01), None
patent: WO 2005/051890 (2005-06-01), None
patent: WO 2005/058848 (2005-06-01), None
patent: WO 2005/063725 (2005-07-01), None
patent: WO 2005/063729 (2005-07-01), None
patent: WO 2005/086661 (2005-09-01), None
patent: WO 2005/087710 (2005-09-01), None
patent: WO 2006/001092 (2006-01-01), None
patent: WO 2006/011615 (2006-02-01), None
patent: WO 2007/123225 (2007-11-01), None
patent: WO 2007/131619 (2007-11-01), None
patent: WO 2007/131620 (2007-11-01), None
patent: WO 2007/131622 (2007-11-01), None
U.S. Appl. No. 11/067,377, filed Feb. 2005, Akerman, et al.
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Science (1999), vol. 286, 531-537.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the Internet, URL; http://www.nlm.nih.gov/medlineplus/cancer.html>.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the Internet, URL; http://en.wikipedia.org/wiki/Cancer>.
Vippagunta, et al. Advanced Drug Delivery Reviews, 48 (2001), 3-26.
Kotarsky et al., “A Human Cell Surface Receptor Activated by Free Fatty Acids and Thiazolidinedione Drugs”,Biochemical and Biophysical Research Communications, 301, 406-410 (2003).
Sawzdargo et al., “A Cluster of Four Novel Human G Protein-Coupled Receptor Genes Occurring in Close Proximity to CD22 Gene on Chromosome 19q13.1”,Biochemical and Biophysical Research Communications, 239, 543-547 (1997).
Berthelot et al., “Synthesis and Pharmalogical Evaluation of y-Aminobutyric Acid Analogues. New Ligand for GABABSites,”J. Med. Chem., 30, 743-746 (1987).
Briscoe et al., “The Orphan G Protein-Coupled Receptor GPR40 is Activated by Medium and Long Chain Fatty Acids,”J. of Biol. Chem., 278(13), 11303-11311 (2003).
DeWolf et al., “Inactivation of Dopamine β-Hydroxylase by β-Ethynyltyramine: Kinetic Characterization and Covalent Modification of an Active Site Peptide,”Biochemistry, 28, 2833-2842 (1989).
Galemmo et al., “The Development of a Novel Series of (Quinolin-2-ylmethoxy) phenyl-Containing Compounds as High-Affinity Leukotriene Receptor Antagonists. 3. Structural Variation of the Acidic Side Chain to Give Antagonists of Enhanced Potency,”J. Med. Chem., 33, 2828-2841 (1990).
Haigh et al., “Non-thiazolidinedione Antihyperglycaemic Agents. Part 3: The Effects of Stereochemistry on the Potency of α-Methoxy-β-phenylpropanoic Acids,”Bioorg.&Med. Chem., 7, 821-830 (1999).
Ishikawa et al., “Actions of the Novel Oral Antidiabetic Agent HQL-975 in Insulin-Resistant Non-Insulin—Dependent diabetes Mellitus Model Animals,”Diabetes Res. and Clin. Pract., 41, 101-111 (1998).
Ishikawa et al., “Effects of the Novel Oral Antidiabetic Agent HQL-975 on Glucose and Lipid Metabolism in Diabetic db/db Mice,”Arzneim. Forsch. Drug Res., 48(3), 245-250 (1998).
Itoh et al., “Free Fatty Acids Regulate Insulin Secretion from Pancreatic β Cells Through GPR40,”Nature, 422, 173-176 (2003).
Kolasa et al., “Symmetrical Bis (heteroarylmethoxyphenyl) alkylcarboxylic Acids as Inhibitors of Leukotriene Biosynthesis,”J. Med. Chem., 43, 3322-3334 (2000).
Iizuka et al., “β-Substituted Phenethylamines as High Affinity Mechanism-Based Inhibitors of Dopamine β-Hydroxylase,”J. Med. Chem., 31, 704-706 (1988).
Kuchar et al., “Benzyloxyarylaliphatic Acids: Synthesis and Quantitative Relations Between Structure and Antiinflammatory Activity,”Collection Czechoslovak Chem, Commun., 47, 2514-2524 (1982).
Kuchar et al., “The Effects of Lopophilicity on the Inhibition of Denaturation of Serum Albumin and on the Activation of Fibrionolysis Observed with a Serixes of Benzyloxyarylaliphatic Acids,”Collection Czechoslovak Chem, Commun., 48, 1077-1088 (1983).
Liu et al., “Synthesis and biological Activity of L-Tyrosine-based PPARγ Agonists with Reduced Molecular Weight,”Bioorg.&Med. Chem. Lett., 11, 3111-3113 (2001).
Oliver et al., A Selective Peroxisome Proliferator-Activated Receptor δ Agonist Promotes Reverse Cholesterol Transport,:PNAS, 98(9), 5306-5311 (2001).
Poitout, Vincent, “The Ins and Outs of Fatty Acids on the Pancreatic β Cells,”Trends in Encocrinology and Metabolism, 14(5), 201-203 (2003).
Shaw et al., “Enantioselective Synthesis of (+)-(2S, 3S)-3-Ethyltyrosine,”Tetrahedron Letters, 31(35), 5081-84 (1990).
Waid et al., “Constrained Amino Acids. An Approach to the Synthesis of 3-Substituted Prolines,”Tetrahedron Letters, 37(24), 4091-4094 (1996).
Dulce M. Garrido et al., “Synthesis and activity of small molecule GPR40 agonists,” Bioorganic & Medicinal Chemistry Letters, 16, 1840-1845 (2006).
International Search Report and Written Opinion from copending PCT/US2006/019545 (2007).
Supplementary Partial European Search Report for copending EP 05723623 by European Patent Office completed on Sep. 7, 2007.
Booth, C. J. et al., “The Synthesis and Transition Temperatures of Novel Low Molar Mass Chosesteric materials Derives from (R)-2-(4-Hydroxyphenoxy)propanoic Acid,” Mol. Cryst. Liq. Cryst., vol. 210, pp. 31-57(1992).
Booth, C. J. et al., “The Influence of the Liquid Crystalline Core Geometry on the Mesogenicity of Novel Chiral 2-(4-Substituted-phenoxy)propanonitriles,” Liquid Crystals, vol. 16(6), pp. 925-940, (1994).
Houze Jonathan
Liu Jiwen
Ma Zhihua
Medina Julio C.
Schmitt Michael J.
Amgen Inc.
Friedrichsen Bernard P.
Saeed Kamal A
Young Shawquia
LandOfFree
Compounds, pharmaceutical compositions and methods for their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, pharmaceutical compositions and methods for their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, pharmaceutical compositions and methods for their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4038345